Tobacco UseNCT04079933
A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product
A study testing Oral tobacco-derived nicotine product (OTDN) in people with Tobacco Use, run by Altria Client Services LLC at 3 sites in United States.
Trial summary
The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively. Read more about this study
- Who is it for?
- Ages 21 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Tobacco Use
- What is being tested?
- Oral tobacco-derived nicotine product (OTDN)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 154 participants
- Where
- 3 sitesUnited States
- Study dates
- 27 Aug 2013to 26 Nov 2013
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subject must:
- sign an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) for the study.
- be between the ages of 21 and 65 years, inclusive, at the time of Screening.
- have consumed a minimum of 10 manufactured cigarettes per day (CPD) daily during the last 6 months (entire 6 month period must have occurred after subject turned 21 years of age).
- indicate that he/she smokes cigarettes "every day" at Screening and on Day 1
- be able to fully comprehend the English language.
Show all 16Show fewer
- have an active phone number and must have daily access to a touchtone phone between 1600 and 1900 hours.
- be interested in alternative tobacco products to cigarettes at Screening.
- indicate that they "definitely would buy" or "probably would buy" on the VBM-FG2 Potential Purchase Interest Questionnaire.
- be in generally good health.
- if female, have a negative urine dipstick pregnancy test.
- if female heterosexually active and of childbearing potential (i.e., not surgically sterile or two years naturally postmenopausal), agree to use a medically accepted method of contraception from Screening through the End of Study.
- have clinical laboratory tests within the appropriate reference range or which are clinically acceptable to the Investigator.
- have a negative ethanol, amphetamines, opiates, cannabinoids, and cocaine urine drug screen.
- test negative for human immunodeficiency (HIV), hepatitis B (hepatitis B surface antigen [HBsAg]), and Hepatitis C (anti-hepatitis C virus antibody [anti-HCV]).
- be willing and able to comply with the requirements of the study.
Who cannot join
- Subject must not:
- be pregnant, nursing, or planning to become pregnant during the study period.
- indicate that he/she intends to quit smoking within the next 30 days (at Screening or on Day 1).
- have uncontrolled hypertension, history of coronary heart disease or other significant heart conditions, and/or other significant medical conditions that might interfere with study procedures.
- have used prescription anti-diabetic medication and/or insulin therapy within 12 months of Day 1.
- have a history of drug or alcohol abuse within the 24 months prior to Screening.
Show all 12Show fewer
- have participated in a clinical study for an investigational drug, device, or biologic within 30 days prior to enrollment (Day 1).
- be a current user of nicotine replacement therapy (indicate every day or some days on Subject Screener/Tobacco History Questionnaire).
- be a current or former employee of the tobacco industry or a first-degree relative (e.g., parent, sibling, child) of a current or former employee of the tobacco industry.
- have been involved in the development of the study design/conduct or be a first-degree relative (e.g., parent, sibling, child) of someone involved in the development of the study design/conduct.
- be a current employee or personnel involved with the study at the study site.
- be currently participating in the study at a different study site (i.e., each subject can only be in the study population once).
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Covance Dallas Clinical Research Unit
Dallas, Texas, 75247
Covance Daytona Clinical Research Unit
Daytona Beach, Florida, 32117
Covance Evansville Clinical Research Unit
Evansville, Indiana, 47710
About this study
Official title: A Randomized, Controlled, Parallel Group Clinical Study of Cigarette Smokers Using an Innovative Oral Tobacco-derived Nicotine Product to Determine Impact on Cigarette Consumption and Biomarkers of Exposure
The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively.
Read the detailed description
This was a randomized, controlled, open-label, parallel group, multicenter, 9-week study to determine changes in BOE in adult smokers allowed ad libitum use of an OTDN product relative to adult smokers who were not allowed to use an OTDN product. This study was conducted in adult smokers who were considered to be in overall good health. Subjects were randomized to Test (allowed OTDN use) or Control (not allowed OTDN use) groups.
- Conditions
- Tobacco Use
- Being tested
- Oral tobacco-derived nicotine product (OTDN)
- Medical subject headings
- Tobacco Use
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral tobacco-derived nicotine product (OTDN)Other
Also called VERVE® Discs Blue Mint, VBM-FG2 oral discs
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Continue Smoking | No intervention | Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks |
| Group 2: OTDN | Experimental | Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint [VBM-FG2]) also under ad libitum conditions Receives: Other: Oral tobacco-derived nicotine product (OTDN) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population)
Summary statistics of percent change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL] (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a Statistical Analysis System (SAS®) procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Secondary outcomes (42)
Summary Statistics of Change From Baseline for Urinary Total NNAL (ng/g Creatinine) (Per-Protocol Population)
Summary statistics of change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL] (ng/g creatinine) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Nicotine Equivalents (mg / g Creatinine) (Per-Protocol Population)
Summary statistics of change from Baseline for urinary nicotine equivalents including nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) (mg/g creatinine) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Nicotine Equivalents (%) (Per-Protocol Population)
Summary statistics of percent change from Baseline for urinary nicotine equivalents including nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for S-phenyl Mercapturic Acid (S-PMA) (ng/g Creatinine) (Per-Protocol Population)
Summary statistics of change from Baseline for urinary S-phenyl mercapturic acid [S-PMA] (ng/g creatinine) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for S-PMA (%) (Per-Protocol Population)
Summary statistics of percent change from Baseline for urinary S-phenyl mercapturic acid [S-PMA] (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)
Summary statistics of change from Baseline for blood carboxyhemoglobin (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)
Summary statistics of percent change from Baseline for blood carboxyhemoglobin (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Exhaled Carbon Monoxide (Ppm) (Per-Protocol Population)
Summary statistics of change from Baseline for exhaled carbon monoxide (ppm) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Exhaled Carbon Monoxide (%) (Per-Protocol Population)
Summary statistics of percent change from Baseline for exhaled carbon monoxide (%) in each study visit are presented.
Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline in Cigarettes Smoked Per Day (Per-Protocol Population)
Summary statistics of change from Baseline in number or products used day in each study visit are presented.
Values for visit are the average of daily values for the previous week Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Cigarettes Smoked Per Day (CPD) (Per-Protocol Population)
Summary statistics of percent change from Baseline of number of products used per day in each study visit are presented.
CPD was tracked using an interactive voice response system (IVRS). During the Baseline Period (Days 1 to 8), subjects reported CPD daily through an IVRS each day between 16:00 and 19:00. Test and Control subjects continued daily tobacco use tracking via an IVRS and return to the study site once a week during the 4 week Product Use Period on Days 15, 22, 29, and 36.
Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing the calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS procedure.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Total Score of Fagerstrom Test for Cigarette Dependence (Per-Protocol Population)
Summary statistics of change from Baseline for Total Score of Fagerstrom Test for Cigarette Dependence at the end of study/early termination are presented. The Fagerstrom Test for Nicotine Dependence consists of Yes/No and multiple-choice questions where each response is assigned a value from 0 to 1 (for yes/no questions) or 0 to 3 (for multiple-choice questions). Values are summed to yield a total score with a minimum score of 0 points and a maximum score of 10 points. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.
Baseline = Visit 3 (Day 8) value Population: Per-Protocol
Measured: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quit Attempts (Per-Protocol)
Count of Test and Control subjects that reported an increase, decrease or no change in quit attempts from Baseline to End of Study are presented. Results for the number of self-reported attempts to quit smoking in the previous 30 days were collected from subject responses to the question "How many times during the past 30 days have you stopped smoking cigarettes for 24 hours or longer because you were trying to quit?".
Baseline = Visit 2 values. Population: Per-Protocol.
Measured: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quitting Intentions (Per-Protocol)
Count of Test and Control subjects that reported a change (No to Yes) or no change in quitting intentions from Baseline to End of Study are presented. Results were collected from subject Yes/No responses to the question "Are you planning to quit smoking in the next 30 days?".
Baseline = Visit 2 responses. Population: Per-Protocol.
Measured: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Difference in Means of Urinary Total NNAL Exposure Between Day 1 and Day 8 (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in mean urinary total NNAL exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Nicotine Equivalents Exposure Between Day 1 and Day 8 (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in mean urinary nicotine equivalents exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of S-PMA Exposure Between Day 1 and Day 8 (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in mean urinary S-phenylmercapturic acid [S-PMA] exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Carboxyhemoglobin (COHb) Exposure Between Day 1 and Day 8 (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in mean blood carboxyhemoglobin [COHb] exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Carbon Monoxide (CO) Exposure Between Day 1 and Day 8 (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in mean exhaled carbon monoxide [CO] between two methods for determining daily product use (Cigarettes Per Day, CPD) during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Difference in Cigarettes Per Day Between the Once Weekly Recall at Day 8 (From Questionnaire) and the Average Daily Tracking Days 2 Through 8 (From IVRS) (Per-Protocol)
This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.
Difference in product use (Cigarettes Per Day [CPD]), including test product, between two methods for determining CPD during the Baseline Period:
Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).
Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).
Population: Per-Protocol.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Frequency and Percentage of Subjects With Change From Baseline in Cigarette Consumption
Change in cigarette consumption, categorized as 'No change', '<50% reduction', '50% to < 100% reduction', '100% reduction' or 'Increase', among subjects in Test and Control groups are presented. Baseline values are based on the average of daily values for the week prior to randomization (Visit 3/Day 8±1).
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Frequency and Percentage of Subjects With Change From Baseline in Urinary Total NNAL (ng / g Creatinine)
Change in Urinary Total NNAL, categorized as 'No change', 'Reduction', 'Increase' or 'Missing', among subjects in Test and Control groups are presented. Baseline values are Visit 3 (Day 8) values.
Measured: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Frequency and Percentage of Subjects With Change From Baseline in Quitting Intentions
Change in subject quitting intentions from Baseline to End of Study are presented. Subject responses were categorized as 'No to Yes', 'Yes to No' and 'Same' (no change in quitting intention). Baseline = Visit 2 (Day 1)
Measured: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Cigarettes Smoked Per Day on Visits 2 (Day 1) and 3 (Day 8)
Summary statistics of average cigarettes smoked per day [CPD] over previous 7 days collected from Cigarette Use questionnaire on Visit 2 (Day 1) and Visit 3 (Day 8) are presented.
Measured: Day 1 (Visit 2) and Day 8 (Visit 3)
Summary Statistics of Carboxyhemoglobin by Study Group and Cigarette Consumption Categories Over Visits
Summary statistics of blood carboxyhemoglobin in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Measured: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Summary Statistics of Exhaled Carbon Monoxide by Study Group and Cigarette Consumption Categories Over Visits
Summary Statistics of exhaled carbon monoxide in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Measured: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Summary Statistics of S-PMA by Study Group and Cigarette Consumption Categories Over Visits
Summary statistics of urinary S-PMA (ng/g creatinine) in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Measured: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Descriptive Statistics for Cigarettes Smoked Per Day (CPD) (Recall Data) in Day 1 and 8 (Respectively) by Study Group and Cigarette Consumption Categories
Descriptive statistics for Cigarettes Smoked per Day (CPD) in Day 1 (Visit 2) and Day 8 (Visit 3) in Test and Control groups using recall data are presented. Subjects were sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing').
Measured: Day 1 (Visit 2) and Day 8 (Visit 3)
Summary Statistics of Cigarettes Smoked Per Day (IVRS Data) by Study Group and Cigarette Consumption Categories on Days 1 Through 8
Summary Statistics of Cigarettes Smoked per Day collected by IVRS Data method on Days 1 to 8 for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Measured: Daily during Baseline Period (Day 1 to Day 8)
Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group
Median change from baseline to End of Study for urinary total NNAL in Test and Control groups are presented. Baseline = Day 8 (Visit 3) values.
Measured: Day 8 (Visit 3) and End of Study (Day 36±1)
Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group and Cigarette Consumption Categories
Median Change from baseline to End of Study for urinary total NNAL in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Day 8 (Visit 3) values
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Change from Baseline to End of Study summary statistics of urinary total NNAL (ng/g Creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (%) by Study Group and Cigarette Consumption Categories Over Visits
Percent change from Baseline to End of study summary statistics of urinary total NNAL (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (mg/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Change from Baseline to End of Study summary statistics of urinary nicotine equivalents (mg/g creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide).
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (%) by Study Group and Cigarette Consumption Categories Over Visits
Percent change from Baseline to End of study summary statistics of urinary nicotine equivalents (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide).
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of S-PMA (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Change from Baseline to End of Study summary statistics of urinary S-phenyl mercapturic acid [S-PMA] (ng/g creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of S-PMA (%) by Study Group and Cigarette Consumption Categories Over Visits
Percent change from Baseline to End of study summary statistics of urinary S-phenyl mercapturic acid [S-PMA] (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits
Change from Baseline to End of Study summary statistics of blood carboxyhemoglobin (%) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits
Percent change from Baseline to End of study summary statistics of blood carboxyhemoglobin (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (Ppm) by Study Group and Cigarette Consumption Categories Over Visits
Change from Baseline to End of Study summary statistics of exhaled carbon monoxide (ppm) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (%) by Study Group and Cigarette Consumption Categories Over Visits
Percent change from Baseline to End of study summary statistics of exhaled carbon monoxide for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.
Baseline = Visit 3 (Day 8) values.
Measured: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Characterization of Subgroups Based on Change From Baseline in Total NNAL
Statistical analyses on the number of subjects in subgroups based on urinary total NNAL change from baseline to the last visit are presented.
Baseline = Visit 3 values.
Measured: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2019
- Study start27 Aug 2013
- Primary completion26 Nov 2013
- Study completion26 Nov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Tobacco UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 154 participants (actual)
Sponsor and investigators
- Lead sponsor
- Altria Client Services LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jeffery S Edmiston, PhD, Study director, Altria Client Services LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04079933
- Sponsor's protocol ID
- COV-VER-01-13
- Status last verified
- May 2024
- First submitted
- 14 Aug 2019
- Last updated
- 27 Sep 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Controlled, Parallel Group Clinical Study of Cigarette Smokers Using an Innovative Oral Tobacco-derived Nicotine Product to Determine Impact on Cigarette Consumption and Biomarkers of Exposure
- ClinicalTrials.gov ID
- NCT04079933
- Acronym / sponsor ID
- COV-VER-01-13
- Conditions
- Tobacco Use
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 154 participants (actual)
- Lead sponsor
- Altria Client Services LLCIndustry (pharma, biotech, devices)
- Study start
- 27 Aug 2013 (actual)
- Primary completion
- 26 Nov 2013 (actual)
- Study completion
- 26 Nov 2013 (actual)
- First posted
- 6 Sep 2019 (actual)
- Results
- Posted 27 Sep 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively.
Detailed description
This was a randomized, controlled, open-label, parallel group, multicenter, 9-week study to determine changes in BOE in adult smokers allowed ad libitum use of an OTDN product relative to adult smokers who were not allowed to use an OTDN product. This study was conducted in adult smokers who were considered to be in overall good health. Subjects were randomized to Test (allowed OTDN use) or Control (not allowed OTDN use) groups.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Continue Smoking | No intervention | –Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks |
| Group 2: OTDN | Experimental | Other: Oral tobacco-derived nicotine product (OTDN)Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint [VBM-FG2]) also under ad libitum conditions |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- sign an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) for the study.
- be between the ages of 21 and 65 years, inclusive, at the time of Screening.
- have consumed a minimum of 10 manufactured cigarettes per day (CPD) daily during the last 6 months (entire 6 month period must have occurred after subject turned 21 years of age).
- indicate that he/she smokes cigarettes "every day" at Screening and on Day 1
- be able to fully comprehend the English language.
Key exclusion criteria (12 listed)
- be pregnant, nursing, or planning to become pregnant during the study period.
- indicate that he/she intends to quit smoking within the next 30 days (at Screening or on Day 1).
- have uncontrolled hypertension, history of coronary heart disease or other significant heart conditions, and/or other significant medical conditions that might interfere with study procedures.
- have used prescription anti-diabetic medication and/or insulin therapy within 12 months of Day 1.
- have a history of drug or alcohol abuse within the 24 months prior to Screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral tobacco-derived nicotine product (OTDN)Also: VERVE® Discs Blue Mint, VBM-FG2 oral discs | Other | Group 2: OTDN |
Primary outcome
Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary statistics of percent change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL] (%) in each study visit are presented. Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1 Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a Statistical Analysis System (SAS®) procedure.
42 secondary outcomes
Summary Statistics of Change From Baseline for Urinary Total NNAL (ng/g Creatinine) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Nicotine Equivalents (mg / g Creatinine) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Nicotine Equivalents (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for S-phenyl Mercapturic Acid (S-PMA) (ng/g Creatinine) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for S-PMA (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Exhaled Carbon Monoxide (Ppm) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Exhaled Carbon Monoxide (%) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline in Cigarettes Smoked Per Day (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Percent Change From Baseline for Cigarettes Smoked Per Day (CPD) (Per-Protocol Population)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Change From Baseline for Total Score of Fagerstrom Test for Cigarette Dependence (Per-Protocol Population)
Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quit Attempts (Per-Protocol)
Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quitting Intentions (Per-Protocol)
Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Difference in Means of Urinary Total NNAL Exposure Between Day 1 and Day 8 (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Nicotine Equivalents Exposure Between Day 1 and Day 8 (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of S-PMA Exposure Between Day 1 and Day 8 (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Carboxyhemoglobin (COHb) Exposure Between Day 1 and Day 8 (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Difference in Means of Carbon Monoxide (CO) Exposure Between Day 1 and Day 8 (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Difference in Cigarettes Per Day Between the Once Weekly Recall at Day 8 (From Questionnaire) and the Average Daily Tracking Days 2 Through 8 (From IVRS) (Per-Protocol)
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Frequency and Percentage of Subjects With Change From Baseline in Cigarette Consumption
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Frequency and Percentage of Subjects With Change From Baseline in Urinary Total NNAL (ng / g Creatinine)
Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Frequency and Percentage of Subjects With Change From Baseline in Quitting Intentions
Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)
Summary Statistics of Cigarettes Smoked Per Day on Visits 2 (Day 1) and 3 (Day 8)
Time frame: Day 1 (Visit 2) and Day 8 (Visit 3)
Summary Statistics of Carboxyhemoglobin by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Summary Statistics of Exhaled Carbon Monoxide by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Summary Statistics of S-PMA by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)
Descriptive Statistics for Cigarettes Smoked Per Day (CPD) (Recall Data) in Day 1 and 8 (Respectively) by Study Group and Cigarette Consumption Categories
Time frame: Day 1 (Visit 2) and Day 8 (Visit 3)
Summary Statistics of Cigarettes Smoked Per Day (IVRS Data) by Study Group and Cigarette Consumption Categories on Days 1 Through 8
Time frame: Daily during Baseline Period (Day 1 to Day 8)
Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group
Time frame: Day 8 (Visit 3) and End of Study (Day 36±1)
Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group and Cigarette Consumption Categories
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (%) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (mg/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (%) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of S-PMA (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of S-PMA (%) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Percent Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (Ppm) by Study Group and Cigarette Consumption Categories Over Visits
Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Tobacco Use
Recruiting
Smoking Cessation in Patients With Cancer
Cancer, Tobacco Use
Recruiting
Pilot Study of Communication for Dual Users of Cigarettes and E-cigarettes
Tobacco Products, Cigarettes
Recruiting
STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking
Tobacco Use, Substance Use Disorders
Recruiting
A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
Smoking, Tobacco
Recruiting
Project Q: Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly or Non-daily
Tobacco Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeffery S Edmiston, PhD study director
Altria Client Services LLC
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oral tobacco-derived nicotine product (OTDN) in people with Tobacco Use, run by Altria Client Services LLC at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Sep 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population) (time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2024.